文献速递前列腺癌

成纤维细胞生长因子受体1驱动前列腺癌的转移进展

Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer.
PubMed 文献 · Eur Urol Oncol · 2021-11-11

该研究采用计算机模拟、体外和体内临床前方法,结合人样本RNA测序与免疫组化,探讨FGFR1及其α/β亚型在前列腺癌骨转移中的作用。小鼠心内注射表达FGFR1的PC3细胞降低生存并增加骨转移发生率,人CRPC骨转移中FGFR1和LAD1表达显著富集,支持FGFR1的促转移效应并为FGFR阻断开发提供路线图。

要点

  • 小鼠心内注射表达FGFR1的PC3细胞降低生存并增加骨转移发生率。
  • 人CRPC骨转移中FGFR1表达较初治非转移原发肿瘤显著富集(p=0.0007)。
  • LAD1在表达FGFR1的PC3细胞中升高,并在人CRPC骨转移中富集(p=0.005)。

核心结论

  • FGFR1表达在实验动物中诱导骨转移,并在人CRPC骨转移中显著富集,支持其在前列腺癌中的促转移效应。
  • 表达FGFR1的促转移PC3细胞中发现的LAD1表达也在CRPC骨转移中富集。
  • 研究支持并为晚期前列腺癌的FGFR阻断开发提供路线图。

研究设计与样本

  • 采用计算机模拟、体外和体内临床前方法,并进行人样本RNA测序和免疫组化研究。

主要发现

  • 小鼠心内注射表达FGFR1α的PC3细胞降低小鼠生存(p<0.0001)并增加骨转移发生率(p<0.0001)。
  • 小鼠心内注射表达FGFR1β的PC3细胞降低小鼠生存(p=0.032)并增加骨转移发生率(p=0.02)。
  • 人CRPC骨转移中FGFR1表达较初治非转移原发肿瘤显著富集(p=0.0007)。
  • 人CRPC骨转移中LAD1表达显著富集(p=0.005)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The diverse mechanisms of progression include fibroblast growth factor (FGF) axis activation. OBJECTIVE: To investigate the molecular and clinical implications of fibroblast growth factor receptor 1 (FGFR1) and its isoforms (α/β) in the pathogenesis of PCa bone metastases. DESIGN, SETTING, AND PARTICIPANTS: In silico, in vitro, and in vivo preclinical approaches were used. RNA-sequencing and immunohistochemical (IHC) studies in human samples were conducted. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: In mice, bone metastases (chi-square/Fisher's test) and survival (Mantel-Cox) were assessed. In human samples, FGFR1 and ladinin 1 (LAD1) analysis associated with PCa progression were evaluated (IHC studies, Fisher's test). RESULTS AND LIMITATIONS: FGFR1 isoform expression varied among PCa subtypes. Intracardiac injection of mice with FGFR1-expressing PC3 cells reduced mouse survival (α, p < 0.0001; β, p = 0.032) and increased the incidence of bone metastases (α, p < 0.0001; β, p = 0.02). Accordingly, IHC studies of human castration-resistant PCa (CRPC) bone metastases revealed significant enrichment of FGFR1 expression compared with treatment-naïve, nonmetastatic primary tumors (p = 0.0007). Expression of anchoring filament protein LAD1 increased in FGFR1-expressing PC3 cells and was enriched in human CRPC bone metastases (p = 0.005). CONCLUSIONS: FGFR1 expression induces bone metastases experimentally and is significantly enriched in human CRPC bone metastases, supporting its prometastatic effect in PCa. LAD1 expression, found in the prometastatic PCa cells expressing FGFR1, was also enriched in CRPC bone metastases. Our studies support and provide a roadmap for the development of FGFR blockade for advanced PCa. PATIENT SUMMARY: We studied the role of fibroblast growth factor receptor 1 (FGFR1) in prostate cancer (PCa) progression. We found that PCa cells with high FGFR1 expression increase metastases and that FGFR1 expression is increased in human PCa bone metastases, and identified genes that could participate in the metastases induced by FGFR1. These studies will help pinpoint PCa patients who use fibroblast growth factor to progress and will benefit by the inhibition of this pathway.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Labanca E, Yang J, Shepherd PDA, et al. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Eur Urol Oncol. 2021. PMID: 34774481. doi:10.1016/j.euo.2021.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。